Overview

Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

Status:
Recruiting
Trial end date:
2024-10-18
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of treatment with either VAY736 or CFZ533 in patients with SLE to enable further development of these compounds as treatment in this disease population
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies, Monoclonal